APA (7th ed.) Citation

Mirza, M., Willmott, L., Hietanen, S., Gilbert, L., Myers, T., Balázs, B., . . . Buscema, J. (2025). Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Gynecologic Oncology, 200, 87. https://doi.org/10.1016/j.ygyno.2025.04.079

Chicago Style (17th ed.) Citation

Mirza, Mansoor, et al. "Updated Duration of Response for Patients Receiving Dostarlimab Plus Carboplatin-paclitaxel Treatment Compared with Patients Receiving Placebo Plus Carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial." Gynecologic Oncology 200 (2025): 87. https://doi.org/10.1016/j.ygyno.2025.04.079.

MLA (9th ed.) Citation

Mirza, Mansoor, et al. "Updated Duration of Response for Patients Receiving Dostarlimab Plus Carboplatin-paclitaxel Treatment Compared with Patients Receiving Placebo Plus Carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial." Gynecologic Oncology, vol. 200, 2025, p. 87, https://doi.org/10.1016/j.ygyno.2025.04.079.